These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 11245461

  • 1. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.
    Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ.
    Cancer Res; 2001 Feb 15; 61(4):1527-32. PubMed ID: 11245461
    [Abstract] [Full Text] [Related]

  • 2. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ.
    Clin Cancer Res; 2002 Sep 15; 8(9):3000-7. PubMed ID: 12231547
    [Abstract] [Full Text] [Related]

  • 3. Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: analysis of the VETOPEC regimen.
    White L, Sterling-Levis K.
    J Clin Neurosci; 2008 Jan 15; 15(1):49-54. PubMed ID: 18036819
    [Abstract] [Full Text] [Related]

  • 4. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
    Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, Travis R, Sausville EA, Houghton PJ.
    Clin Cancer Res; 2001 Jun 15; 7(6):1758-64. PubMed ID: 11410517
    [Abstract] [Full Text] [Related]

  • 5. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
    Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.
    Anticancer Res; 2008 Jun 15; 28(6A):3801-8. PubMed ID: 19189667
    [Abstract] [Full Text] [Related]

  • 6. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G, Boland I, Terrier-Lacombe MJ, Watson AJ, Margison GP, Vénuat AM, Morizet J, Parker F, Lacroix C, Lellouch-Tubiana A, Pierre-Kahn A, Poullain MG, Gouyette A.
    Clin Cancer Res; 1998 Feb 15; 4(2):463-8. PubMed ID: 9516937
    [Abstract] [Full Text] [Related]

  • 7. Caffeine and staurosporine enhance the cytotoxicity of cisplatin and camptothecin in human brain tumor cell lines.
    Janss AJ, Levow C, Bernhard EJ, Muschel RJ, McKenna WG, Sutton L, Phillips PC.
    Exp Cell Res; 1998 Aug 25; 243(1):29-38. PubMed ID: 9716446
    [Abstract] [Full Text] [Related]

  • 8. Medulloblastoma/primitive neuroectodermal tumour studied as a Matrigel enhanced subcutaneous xenograft model.
    White L, Sterling-Levis K, Kees UR, Tobias V.
    J Clin Neurosci; 2001 Mar 25; 8(2):151-6. PubMed ID: 11484666
    [Abstract] [Full Text] [Related]

  • 9. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
    Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M.
    Clin Cancer Res; 2003 Aug 01; 9(8):2887-92. PubMed ID: 12912932
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth.
    Gallicchio MA, van Sinderen M, Bach LA.
    Horm Metab Res; 2003 Aug 01; 35(11-12):822-7. PubMed ID: 14710364
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.
    Clin Cancer Res; 2009 Apr 15; 15(8):2777-88. PubMed ID: 19351762
    [Abstract] [Full Text] [Related]

  • 12. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.
    Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, Joukhadar C.
    Pharmacology; 2007 Apr 15; 79(4):207-13. PubMed ID: 17377418
    [Abstract] [Full Text] [Related]

  • 13. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
    Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA.
    Cancer; 2009 Sep 01; 115(17):3887-96. PubMed ID: 19484784
    [Abstract] [Full Text] [Related]

  • 14. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 15. [Rapamycin and CCI-779].
    Alexandre J, Raymond E, Armand JP.
    Bull Cancer; 1999 Oct 15; 86(10):808-11. PubMed ID: 10572230
    [Abstract] [Full Text] [Related]

  • 16. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.
    Lee L, Sudentas P, Dabora SL.
    Genes Chromosomes Cancer; 2006 Oct 15; 45(10):933-44. PubMed ID: 16845661
    [Abstract] [Full Text] [Related]

  • 17. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V.
    Clin Cancer Res; 2006 Nov 15; 12(22):6781-90. PubMed ID: 17121899
    [Abstract] [Full Text] [Related]

  • 18. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 19. The role of xenografting in pediatric brain tumor research with specific emphasis on medulloblastoma/primitive neuroectodermal tumors of childhood.
    Sterling-Levis K, White L.
    In Vivo; 2003 May 15; 17(4):329-42. PubMed ID: 12929588
    [Abstract] [Full Text] [Related]

  • 20. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L, Birle DC, Tannock IF.
    Cancer Res; 2005 Apr 01; 65(7):2825-31. PubMed ID: 15805283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.